Penn Davis Mcfarland Inc. Grows Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

Penn Davis Mcfarland Inc. lifted its position in Roivant Sciences Ltd. (NASDAQ:ROIV) by 1.0% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 1,649,026 shares of the company’s stock after purchasing an additional 16,832 shares during the period. Roivant Sciences comprises approximately 2.1% of Penn Davis Mcfarland Inc.’s portfolio, making the stock its 20th biggest holding. Penn Davis Mcfarland Inc.’s holdings in Roivant Sciences were worth $19,508,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in ROIV. Mutual of America Capital Management LLC boosted its position in Roivant Sciences by 0.4% during the 2nd quarter. Mutual of America Capital Management LLC now owns 327,079 shares of the company’s stock valued at $3,457,000 after buying an additional 1,142 shares during the period. GAMMA Investing LLC raised its stake in shares of Roivant Sciences by 57.0% during the fourth quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock valued at $42,000 after acquiring an additional 1,288 shares during the last quarter. Acadian Asset Management LLC boosted its holdings in shares of Roivant Sciences by 23.2% during the second quarter. Acadian Asset Management LLC now owns 8,510 shares of the company’s stock worth $89,000 after purchasing an additional 1,603 shares during the period. Covestor Ltd grew its stake in shares of Roivant Sciences by 9.1% in the third quarter. Covestor Ltd now owns 19,190 shares of the company’s stock worth $222,000 after purchasing an additional 1,605 shares during the last quarter. Finally, US Bancorp DE grew its stake in shares of Roivant Sciences by 146.5% in the third quarter. US Bancorp DE now owns 3,278 shares of the company’s stock worth $38,000 after purchasing an additional 1,948 shares during the last quarter. 64.76% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Roivant Sciences

In related news, Director Sciences Ltd. Roivant purchased 16,845,010 shares of the company’s stock in a transaction dated Monday, January 13th. The shares were purchased at an average cost of $20.00 per share, with a total value of $336,900,200.00. Following the transaction, the director now directly owns 96,650,341 shares in the company, valued at $1,933,006,820. This trade represents a 21.11 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CIO Mayukh Sukhatme sold 412,584 shares of the business’s stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $12.05, for a total value of $4,971,637.20. Following the completion of the sale, the executive now directly owns 18,836,547 shares in the company, valued at $226,980,391.35. This trade represents a 2.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,842,629 shares of company stock valued at $21,906,486. 7.90% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a research report on Wednesday, November 13th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, Roivant Sciences has an average rating of “Moderate Buy” and a consensus target price of $17.93.

Roivant Sciences Price Performance

Shares of NASDAQ ROIV opened at $11.15 on Monday. Roivant Sciences Ltd. has a 1 year low of $9.69 and a 1 year high of $13.06. The stock has a market capitalization of $8.12 billion, a P/E ratio of 1.97 and a beta of 1.27. The company’s 50-day moving average is $11.79 and its 200 day moving average is $11.60.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.